{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:09:12Z","timestamp":1761505752503,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cllc.2013.12.003","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T16:32:18Z","timestamp":1388766738000},"page":"231-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thymic Epithelial Neoplasms: A 12-Year Canadian Regional Cancer Program Experience"],"prefix":"10.1016","volume":"15","author":[{"given":"Paul","family":"Wheatley-Price","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Shamji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio M.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2013.12.003_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","article-title":"The management of thymoma: a systematic review and practice guideline","volume":"4","author":"Falkson","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2011.11.010","article-title":"State-of-the-art classification and\u00a0multimodality treatment of malignant thymoma","volume":"38","author":"Koppitz","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2013.12.003_bib4","first-page":"136","article-title":"Postoperative radiotherapy for stage I\u00a0thymoma: a prospective randomized trial in 29 cases","volume":"112","author":"Zhang","year":"1999","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cllc.2013.12.003_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","article-title":"EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma","volume":"16","author":"Bonomi","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide, ifosfamide, and\u00a0cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.bmt.1703181","article-title":"High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience","volume":"28","author":"Hanna","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cllc.2013.12.003_bib9","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A\u00a0phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib10","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib11","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and\u00a0cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib13","first-page":"208","article-title":"Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results","volume":"25","author":"Oshita","year":"1995","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A\u00a0phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib16","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib17","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib18","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone\u00a0or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"Palmieri","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2013.12.003_bib21","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002371-199510000-00005","article-title":"A\u00a0phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed\/refractory thymoma","volume":"18","author":"Gordon","year":"1995","journal-title":"J\u00a0Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.cllc.2013.12.003_bib23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","article-title":"The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients","volume":"94","author":"Okumura","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib24","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.cllc.2013.12.003_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijrobp.2009.02.016","article-title":"Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease","volume":"76","author":"Forquer","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2013.12.003_bib27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.ijrobp.2011.03.010","article-title":"Evaluation of the role of radiation therapy in the management of malignant thymoma","volume":"82","author":"Patel","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2013.12.003_bib28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00000478-200005000-00014","article-title":"CD70 expression in thymic carcinoma","volume":"24","author":"Hishima","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2013.12.003_bib29","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ijc.22078","article-title":"COX-2 upregulation in thymomas and thymic carcinomas","volume":"119","author":"Rieker","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib30","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"10 suppl 4","key":"10.1016\/j.cllc.2013.12.003_bib31","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","article-title":"Thymoma and thymic carcinoma: molecular pathology and targeted therapy","volume":"5","author":"Strobel","year":"2010","journal-title":"J\u00a0Thorac Onco"},{"issue":"10 suppl 4","key":"10.1016\/j.cllc.2013.12.003_bib32","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors: relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib33","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2013.12.003_bib36","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J\u00a0Clin Onco"},{"key":"10.1016\/j.cllc.2013.12.003_bib37","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2013.12.003_bib38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0002-9440(10)64426-4","article-title":"Chromosome 6 suffers frequent and multiple aberrations in thymoma","volume":"161","author":"Inoue","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cllc.2013.12.003_bib39","first-page":"3708","article-title":"Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas","volume":"63","author":"Inoue","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2013.12.003_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9440(10)64536-1","article-title":"Recurrent genetic aberrations in thymoma and thymic carcinoma","volume":"157","author":"Zettl","year":"2000","journal-title":"Am J Pathol"},{"issue":"10 suppl 4","key":"10.1016\/j.cllc.2013.12.003_bib41","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1097\/JTO.0b013e3181f22d01","article-title":"International thymic malignancies interest group: a way forward","volume":"5","author":"Detterbeck","year":"2010","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041300260X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041300260X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:03:53Z","timestamp":1761505433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573041300260X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S152573041300260X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2013.12.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymic Epithelial Neoplasms: A 12-Year Canadian Regional Cancer Program Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2013.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}